Abstract: FR-PO1102
Systematic Assessment of the Urine Dipstick Glucose-Serum Uric Acid Relationship: Evidence from a Cross-Sectional Study of 249,977 Taiwanese Adults
Session Information
- Health Maintenance, Nutrition, and Metabolism
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Health Maintenance, Nutrition, and Metabolism
- 1500 Health Maintenance, Nutrition, and Metabolism
Authors
- Lin, Ming-Hsien, Division of Nephrology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
- Chiang, Hsiu-Yin, Big Data Center, China Medical University Hospital, Taichung, Taiwan
- Wu, Jia-Ling, Division of Nephrology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
- Chang, David R., Division of Nephrology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
- Kuo, Chin-Chi, Big Data Center, China Medical University Hospital, Taichung, Taiwan
Background
Growing epidemiological evidence supports the hypothesis of glycosuria-mediated uricosuria; however, prior studies have been limited by small sample sizes and a focus primarily on diabetic populations. This study aimed to systematically characterize the relationship between urine dipstick glucose (UDG) and serum uric acid (SUA) levels in a large hospital-based Taiwanese population.
Methods
Adult patients who had their first UDG measurements between 2003 and 2022 at the iHi Platform of China Medical University Hospital were included. Patients with recent use of urate-lowering agents, diuretics, or sodium-glucose cotransporter-2 inhibitors (SGLT2i), and those with a history of end-stage kidney disease, were excluded. SUA measurements taken within ±6 months of the UDG test, with the value closest to the UDG date, were used to define the index SUA level. Hyperuricemia was defined as SUA >7 mg/dL in males and >6 mg/dL in females. A multivariable linear regression model was used to assess the association between UDG categories and SUA levels among all eligible patients. Subgroup analyses were conducted based on age, sex, body mass index (BMI), smoking status, alcohol use, and baseline comorbidities.
Results
Of 249,977 eligible patients, 241,019 (mean age 46±16 years; 53% male), 3,135 (59±16 years; 63%), 1,720 (61±15 years; 65%), and 4,103 (58±15 years; 66%) had UDG levels of negative, 1+, 2+, and 3+, respectively. Corresponding SUA levels were 5.8±1.6, 5.7±0.2, 5.6±1.9, and 5.3±1.9 mg/dL, with hyperuricemia rates of 24%, 26%, 23%, and 18% (both p-trend <0.001). In the UDG 3+ category, the adjusted average SUA level was 0.84 mg/dL lower (95% CI: 0.76–0.93) compared to the negative category. Patients aged ≤65, with alcohol use, BMI <27, no baseline chronic kidney disease, or diabetes showed stronger inverse associations between UDG categories and SUA levels.
Conclusion
Our findings support glycosuria-mediated attenuation of SUA across diverse demographic and comorbidity profiles. As glycosuria can now be pharmacologically induced by SGLT2i, future research should explore whether the benefits of SGLT2i are partly driven by modulation of SUA-related pathogenic pathways.